33
https://pubmed.ncbi.nlm.nih.gov/38093030
Adjuvant olaparib is a cost-effective treatment compared to watch and wait for patients with high-risk, HER2-negative early breast cancer with germline BRCA1/2 mutations in Sweden, as it provides more life-years and quality-adjusted life-years at an acceptable incremental cost.
